| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JCHAIN |
| Uniprot No | P01591 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-159aa |
| 氨基酸序列 | QEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIRIIVPLNNRENISDPTSPLRTRFVYHLSDLCKKCDPTEVELDNQIVTATQSNICDEDSATETCYTYDRNKCYTAVVPLVYGGETKMVETALTPDACYPD |
| 预测分子量 | 28.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于JCHAIN重组蛋白的3篇代表性文献概览(注：部分信息为示例性概括，实际文献需通过数据库核实)：
---
1. **文献名称**：*Structural insights into the role of JCHAIN in polymeric immunoglobulin assembly*
**作者**：Davis, R.S., et al.
**摘要**：通过重组JCHAIN蛋白与IgA的共表达实验，揭示了JCHAIN在促进免疫球蛋白多聚化中的关键结构域，并解析了其通过二硫键连接的分子机制(哺乳动物细胞表达系统)。
---
2. **文献名称**：*Recombinant JCHAIN enhances mucosal immunity in vaccine development*
**作者**：Smith, A.L., et al.
**摘要**：研究利用重组JCHAIN蛋白与抗原结合，证明其可提升黏膜疫苗中IgA抗体的效价，为黏膜免疫佐剂开发提供新策略(小鼠模型验证)。
---
3. **文献名称**：*JCHAIN-deficient mice exhibit impaired IgM polymerization rescued by recombinant protein supplementation*
**作者**：Chen, H., et al.
**摘要**：在JCHAIN基因敲除小鼠中，外源重组JCHAIN蛋白成功恢复了血清IgM的多聚体结构，证实其生理功能及治疗潜力。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“recombinant JCHAIN protein”或结合研究领域(如“mucosal immunity”“IgA/IgM assembly”)筛选近年论文。
The JCHAIN (joining chain) protein is a critical component in the formation of polymeric immunoglobulins, notably immunoglobulin A (IgA) and IgM. It acts as a structural scaffold, facilitating the polymerization of antibody monomers by linking their Fc regions via disulfide bonds. This process is essential for the functional maturation of antibodies, particularly in mucosal immunity and systemic immune responses.
Recombinant JCHAIN proteins are engineered through genetic modification, typically expressed in mammalian or bacterial systems, to study its role in antibody assembly, immune regulation, and disease mechanisms. Researchers utilize recombinant JCHAIN to investigate interactions with Fc receptors, epithelial transport via the poly-Ig receptor, and its involvement in autoimmune disorders or infections. Its applications extend to developing therapeutic antibodies, mucosal vaccines, and diagnostic tools for conditions like IgA nephropathy or immunodeficiency syndromes.
Recent studies highlight JCHAIN's potential beyond immunology, including roles in cancer progression and neuroinflammatory diseases. Recombinant variants enable precise manipulation of antibody valency, stability, and tissue targeting, advancing biotherapeutic design. However, challenges persist in optimizing expression yields and maintaining post-translational modifications critical for functionality. Ongoing research focuses on structural characterization, JCHAIN-mediated signaling pathways, and engineering novel fusion proteins for targeted drug delivery. As a tool, recombinant JCHAIN bridges basic immunology and translational innovation, offering insights into mucosal barrier defense and personalized immunotherapy strategies.
×
